Septa Pharmaceuticals Expands Portfolio with Acquisition of CeeNU® from Bristol Myers Squibb

Septa Pharmaceuticals Expands Its Product Offering

On July 15, 2026, Septa Pharmaceuticals Inc., a prominent and rapidly growing player in the Canadian healthcare market, proudly announced the successful acquisition of CeeNU® (Lomustine) from Bristol Myers Squibb. This acquisition, finalized on June 29, 2026, marks a significant milestone in Septa's ongoing expansion efforts and underscores its commitment to enhancing its portfolio of specialized oncology pharmaceuticals.

CeeNU® (Lomustine) is an established alkylating agent renowned for its efficacy in treating certain types of brain tumors and Hodgkin lymphoma. By integrating this essential chemotherapeutic drug into its product line, Septa is solidifying its presence within the critical care and oncology sectors, where treatments can be life-saving for many patients.

The importance of CeeNU® cannot be overstated. For many individuals battling grave illnesses, it represents a vital therapeutic option. Thus, Septa is determined to ensure continuous and uninterrupted access to CeeNU® across Canada. In today's complex healthcare landscape where the demand for stable supplies of essential medications is ever-increasing, guaranteeing the long-term availability of Lomustine is a top priority for the company.

Devinder K., the CEO of Septa Pharmaceuticals Inc., stated, "As we integrate CeeNU® (Lomustine) into our growing portfolio, our main focus remains resolutely on the patients and the healthcare professionals who treat them. We are working collaboratively and closely with all relevant stakeholders, including regulatory bodies and supply chain partners, to ensure a smooth transition. This acquisition is a profound testament to our core mission: providing reliable, high-quality pharmaceuticals that significantly improve health outcomes across the nation and globally."

Septa Pharmaceuticals is not merely resting on its laurels. As it rapidly diversifies its product portfolio and extends its geographical reach, the company is actively seeking new strategic partnerships and licensing opportunities. They are keen to collaborate with other pharmaceutical firms to acquire licenses and to launch and market impactful therapies globally. Through these collaborations, Septa aims to foster mutual growth and ensure that essential medications reach global markets promptly.

About Septa Pharmaceuticals Inc.
Based in Ontario, Canada, Septa Pharmaceuticals Inc. is an innovative pharmaceutical company dedicated to the development, acquisition, and commercialization of specialized pharmaceutical products worldwide. With a patient-centered philosophy, Septa continually works to address healthcare marketplace deficiencies by stabilizing the supply of essential medications. Through strategic alliances and acquisitions, Septa continues to build a robust portfolio of products and controlled access programs designed to meet the ever-evolving needs of the global medical community.

As Septa looks toward the future, the integration of CeeNU® (Lomustine) into its lineup serves as a crucial step in enhancing the overall healthcare landscape in Canada, ensuring that patients receive the medications they need while reinforcing Septa’s position as a leader in high-quality pharmaceutical care.